13F Holdings
中文EN

LEXX Lexaria Bioscience Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1348362 · Fiscal year ends 08/31

Financial factors as of 2026-05-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-68.5%
TTM net income YoY32.1%
TTM EPS YoY50.0%
Revenue 3-yr CAGR-14.2%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-3,973.2%
Net margin-3,985.6%
FCF margin-3,848.6%
EBITDA margin-3,960.4%

Returns

ROE-150.3%
ROA-134.2%
ROIC (approx.)-553.9%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets9.1%
Debt / equity0.00x
Current ratio10.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue21.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-08-31FY20242024-08-31FY20232023-08-31FY20222022-08-31FY20212021-08-31
Income statement
Revenue$705,923$464,278$226,208$255,397$722,738
Cost of revenue$2,720$4,822$31,500$71,841$175,346
Gross profit$703,203$459,456$194,708$183,556$547,392
R&D expense$8.24M$2.36M$3.67M$1.84M$1.26M
SG&A expense$4.35M$3.85M$3.06M$4.96M$4.97M
Operating income-$11.88M-$5.75M-$6.53M-$6.62M-$5.69M
Interest expense—$7,760$0——
Pretax income-$11.91M-$5.81M-$6.71M-$7.38M-$4.17M
Income tax———$0$6,093
Net income-$11.90M-$5.80M-$6.66M-$7.27M-$4.03M
EBITDA-$11.83M-$5.71M-$6.39M-$6.52M-$5.58M
EPS (basic)————-0.95
EPS (diluted)-0.66-0.47-1.01—-0.95
Weighted avg. shares (diluted)18.00M12.38M6.61M—4.39M
Banking
Net interest income—$14,311$43,190——
Noninterest income——$43,190$0—
Balance sheet
Cash & equivalents$1.80M$6.50M$1.35M$5.81M$10.92M
Short-term investments$143,267$55,807$125,642$347,335$833,841
Receivables$368,358$154,477$126,686$201,784$342,401
Inventory——$0$38,418$29,648
Current assets$3.47M$7.90M$2.15M$6.98M$12.44M
PP&E, net$228,129$254,709$254,143$315,505$368,213
Intangibles$307,818$516,676$462,625——
Total assets$4.18M$8.87M$3.08M$7.83M$13.27M
Current liabilities$1.49M$1.10M$267,735$194,036$153,276
Total liabilities$1.57M$1.21M$403,908$201,437$203,265
Shareholders' equity$2.99M$8.04M$3.04M$7.95M$13.06M
Shares outstanding19.56M19.56M8.09M5.95M5.73M
Cash flow statement
Operating cash flow-$10.45M-$4.96M-$5.88M-$4.88M-$3.99M
Capital expenditure$24,646$43,014$33,748$49,192—
Free cash flow-$10.48M-$5.00M-$5.91M-$4.93M—
Investing cash flow-$243,019-$188,605-$169,610-$180,640$193,880
Financing cash flow$6.05M$10.32M$1.59M-$44,600$13.42M
Depreciation & amortization$51,225$42,448$145,397$102,718$111,718
Stock-based compensation$859,494$492,236$170,382$752,591$410,007

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.